<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100839</url>
  </required_header>
  <id_info>
    <org_study_id>LPMX-112</org_study_id>
    <nct_id>NCT02100839</nct_id>
  </id_info>
  <brief_title>Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LipimetiX Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LipimetiX Development, LLC</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the first part of this study is to determine the safety and tolerability of a
      single dose of AEM-28, an apolipoprotein E mimetic, in subjects with high total cholesterol
      who are otherwise healthy subjects. The pharmacokinetics and pharmacodynamics of AEM-28 will
      also be evaluated.

      The second part of this study will be a multiple ascending dose evaluation of AEM-28 in
      patients with refractory hypercholesterolemia.

      AEM-28 has demonstrated significant lipid lowering activity and positive effects on the
      artery wall. AEM-28 is being developed for the treatment of homozygous familial
      hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>From 1st dose, Day 1, to Day 8 for SAD study; From 1st dose, Day 1, to Day 57 for MAD study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of adverse events (i.e. seriousness, severity, relationship to AEM-28), vital signs, ECG, clinical laboratory parameters, physical examinations, local response to each injection and body weight.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipoproteinemia Type II</condition>
  <arm_group>
    <arm_group_label>AEM-28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL
Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Ascending Dose: Single IV dose for each cohort.
Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEM-28</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>AEM-28</arm_group_label>
    <other_name>apolipoprotein E mimetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% saline for injection</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>0.9% NaCl</other_name>
    <other_name>Sterile Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        SAD Study:

          -  Male or female non-smoker, ≥18 and ≤55 years of age, with BMI &gt;18.5 and &lt; 32.0 kg/m²

          -  Total cholesterol greater or equal to 5.0 mmol/L (≥194 mg/dL) at screening

        MAD Study:

          -  Male or female non-smoker, ≥18 and ≤75 years of age, with BMI &gt;18.5 and &lt; 35.0 kg/m²

          -  Diagnosis of refractory hypercholesterolemia with LDL cholesterol levels &gt; 2.5 mmol/L
             (97 mg/mL) at screening.

          -  On stable lipid lowering therapy for  ≥ 8 weeks

          -  On stable diet for  ≥ 12 weeks.

        Exclusion Criteria:

        SAD Study:

          -  Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening or positive test for hepatitis B, hepatitis C, or HIV found
             during medical screening.

          -  History of allergic reactions to diphenhydramine, ranitidine, methylprednisone or
             other related drugs, or history of significant allergic or hypersensitivity reaction
             (e.g. angioedema) to any substance.

        MAD Study:

          -  Significant health problems within 6 months prior to screening, which in the opinion
             of the Medical Sub-Investigator would prevent the subject from participating in the
             study, including but not limited to: unstable coronary heart disease; transient
             ischemic attack; stroke; revascularization procedure; uncontrolled hyperthyroidism;
             coagulation disorder; peptic ulcers or GI bleeding; significant disease of the
             central nervous system; liver or renal disease.

          -  History of allergic reactions to diphenhydramine, ranitidine, methylprednisone or
             other related drugs, or history of significant allergic or hypersensitivity reaction
             (e.g. angioedema) to any substance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janakan Krishnarajah, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janakan Krishnarajah, MBBS, FRACP</last_name>
      <phone>+61 8 6382 5100</phone>
      <email>contactus@linear.org.au</email>
    </contact>
    <investigator>
      <last_name>Janakan Krishnarajah, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>apolipoprotein E</keyword>
  <keyword>First in Human</keyword>
  <keyword>ApoE</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
